Varenicline: Efficacy, Precaution, and Safety in Smoking Cessation

	Varenicline: Efficacy, Precaution, and Safety in Smoking Cessation
Advances in Pharmacology and Therapeutics Journal
Article 3, Volume 4, Issue 1 - Serial Number 7, October 2024, Pages 18-20 PDF (210.58 K)
Document Type: Letter to editor
DOI: 10.18502/aptj.v4i1.16713
Authors
habibollah afshang; Reza Bidaki^*
Abstract
Varenicline is a medication used to help people quit smoking when used in conjunction with education and counseling. It is the first-line treatment for smoking cessation and is available in 0.5 mg and 1 mg strength oral tablets. Varenicline is primarily eliminated via the kidney through glomerular filtration, and its excretion is via the renal route, so it is important to monitor renal function before and during treatment. Varenicline has been associated with an increased risk of new psychiatric conditions, anxiety, and mood disorders in some individuals. The use of Varenicline should be accompanied by close monitoring and careful consideration of individual patient factors. While Varenicline can be used in a wide range of patients, its use should be carefully considered in patients with heart or blood vessel disease, renal impairment, psychiatric disorder, or seizure.
Keywords
Varenicline; Smoking Cessation; Psychiatric; Renal Failure; Cardiovascular Diseases

Statistics Article View: 39 PDF Download: 51